Detection of minimal residual disease in acute myeloid leukemia.

被引：8
作者：
Baer M.R. [1 ]
机构：
[1] Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, 14263, NY
来源：
Current Oncology Reports | 2002年 / 4卷 / 5期
关键词：
Acute Myeloid Leukemia; Residual Disease; Acute Promyelocytic Leukemia; Minimal Residual Disease; Acute Myeloid Leukemia Patient;
D O I：
10.1007/s11912-002-0033-z
中图分类号：
学科分类号：
摘要：
Acute myeloid leukemia (AML) is a curable malignancy, but its cure rate remains disappointingly low. Accurate quantitation of residual AML cells would allow individualization of therapy and thereby increase the likelihood of cure for each patient. Techniques that are being studied for residual disease detection include molecular assays for abnormalities that are present in subsets of AML patients, and multiparameter flow cytometry, which has broader applicability. Although significant advances have been made in the development of assays for monitoring residual disease, and particularly in techniques for molecular quantitation, additional refinement and validation are needed before these assays can be applied routinely in clinical management.
引用
收藏
页码：398 / 402
页数：4
相关论文
共 77 条
[1]  
Strehl S(2001)Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia Blood 97 805-808
[2]  
König M(2001)Prognostic significance of minimal residual disease detection and PML/RARa isoform type: long-term follow-up in acute promyelocytic leukemia Blood 98 2651-2656
[3]  
Mann G(2001)The PML-RARa transcript in long-term follow-up of acute promyelocytic leukemia patients Haematologica 86 577-585
[4]  
Haas OAL(2001)Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RT-PCR method Leukemia 15 1060-1065
[5]  
Jurcic JG(2001)Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction J Mol Diagn 3 141-149
[6]  
Nimer SD(2000)Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse Blood 95 815-819
[7]  
Scheinberg DA(2001)Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting Leukemia 15 1408-1414
[8]  
Gameiro P(1996)Persistence of multipotent progenitors expressing AML1/ETO transcripts in longterm remission patients with t(8;21) acute myelogenous leukemia Blood 87 4789-4796
[9]  
Vieira S(2000)AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation Proc Natl Acad Sci U S A 97 7521-7526
[10]  
Carrara P(2000)Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia Leukemia 14 329-335
12345678